Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. - Wikidata - wikimedia - TriplyDB

Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.

Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.

http://www.wikidata.org/entity/Q36601787

about

Breast cancer pain management - a review of current & novel therapies Suivi après le traitement du cancer du sein: Guide pratique des soins aux survivantes à l’intention des médecins de famille Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians Pain in cancer survivors Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors The JACS prospective cohort study of newly diagnosed women with breast cancer investigating joint and muscle pain, aches, and stiffness: pain and quality of life after primary surgery and before adjuvant treatment.Nongenomic signaling pathways of estrogen toxicity.Cancer, physical activity, and exercise Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.Validation of QuickDASH outcome measure in breast cancer survivors for upper extremity disability.Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors Online discussion of drug side effects and discontinuation among breast cancer survivors Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol.The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.Black breast cancer survivors experience greater upper extremity disability Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis.Uncovering the expectancy effect: the validation of the acupuncture expectancy scale CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Anastrozole-associated joint pain and other symptoms in patients with breast cancer.Predictors of yoga use among patients with breast cancer.Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.Breast cancer survivorship symptom management: current perspective and future development.Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.Weight management and its role in breast cancer rehabilitation.Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors.

P2860

Q27008950-1C89B769-3372-4D0E-94AE-CDCC9B417219 Q28078524-7B7DB98D-2354-4BF9-8B10-E7C439CAE32A Q28080263-E23A8043-1153-4C08-B7D1-44CDA7BD30E1 Q33650576-94831EC1-E572-48B0-88BD-F848CA29D125 Q33714141-27AE4378-24E9-4464-8C14-375ECD5388D6 Q33826701-BB2E760A-ACD7-48D2-B5EC-180ECD9AF838 Q33988964-70C39496-862F-4BCE-B38F-434CA1D1929A Q34004946-2638429D-CDBD-4C90-B827-B2E8A31E45A2 Q34020925-9EE07AAB-DEA1-459F-A94F-7C4B565069BB Q34045510-41F8818D-74A9-4FA1-B9FD-A0CBD667B38F Q34116012-D8B58DBE-E668-4CE4-B88C-FD66CE58BEF0 Q34434858-AD203161-5E15-431F-B09C-3EC674D0899F Q34437529-0657FE38-E4B2-4563-BF1C-B2DBAD66E182 Q34551060-0E2BEE0B-36BF-49A4-8FCE-EFC1E9602B70 Q34903656-55B19663-340D-4133-8D4B-D256923264A7 Q34978227-37BC9592-104C-4B3E-8596-0FCE5B890272 Q35029533-70D67703-9AD5-4661-BB04-5E88F0A7F59A Q35215032-298D83F8-D62F-400B-8373-0E64D1B2BB90 Q35233959-F9178CBD-8B7A-4259-84F9-8F6EF24DB7DC Q35558893-C80CB3ED-8EB8-41DA-B837-F9326C52A2F5 Q35573002-CDDAB2B0-08C0-4831-AD52-20C3FBEAF30E Q35671362-CC99FC40-C3DD-4C43-B56B-513C7DFE9BEB Q35687686-A138F64B-043F-432E-A054-D56324DA1196 Q35742054-48E41C22-8E3B-466A-BC85-8676D6D159A0 Q35857652-F4DD8D0D-A360-4E23-9EF4-A5F20CFB6136 Q35925132-BFC93378-5C57-4AE8-9CB3-21E4D04CF35F Q36217990-15F38A24-48F5-4876-9EA6-D377E4734663 Q36282120-A6D41DA2-FF88-4EBC-BE76-65F6DF370E1F Q36601795-76F33079-86C6-4239-B6A8-196FD991C41D Q36606068-0A2AB025-AA4E-4820-A999-5807FC5DA0BE Q36655900-C0F5F99C-ABF1-4FD8-A864-02A08F5DC326 Q36692639-486F29AA-DBEC-4E22-BC1E-92064E4DED51 Q36692645-9FFDBF6A-F8C4-48F2-9E65-30EA5DF6895E Q36823146-F5CC887D-4725-41C6-83D2-EBA487A8A491 Q36876171-0EA5B47B-3158-4346-98F6-CB3DF250D35F Q36884366-4F310BED-77AE-4BBF-A6DB-7307157E5277 Q36956837-C44DDF2C-C78A-448D-AFB2-CCAB3394F6F9 Q37261579-FB9DFF44-AEE5-4886-8057-C83696C33C7E Q37267393-9CB397D1-54BE-4C26-B05E-D572139A2510 Q37325279-B9232C93-3050-40B2-B2BE-D12A7473F062

P2860

Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.

http://www.wikidata.org/entity/Q36601787

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Patterns and risk factors asso ...... among breast cancer survivors.

@ast

Patterns and risk factors asso ...... among breast cancer survivors.

@en

type

label

Patterns and risk factors asso ...... among breast cancer survivors.

@ast

Patterns and risk factors asso ...... among breast cancer survivors.

@en

prefLabel

Patterns and risk factors asso ...... among breast cancer survivors.

@ast

Patterns and risk factors asso ...... among breast cancer survivors.

@en

P1433

Q36601787-7E765826-76E5-456A-8571-CC9419BFF5A1

P1476

Q36601787-6DDB3C39-8199-4CDD-BF67-1D0778413B57

P2093

Q36601787-0BEAAAEB-66D6-45D1-A39E-6BDD9CDB4E6C

Q36601787-3DC0EEEC-4FFB-4054-802C-5890319747AF

Q36601787-7452066A-B0C4-4DF9-BD69-0A8F053CAF6E

Q36601787-767C5F8B-7F89-4D3D-AA05-4BCBF47511B2

Q36601787-863873CF-4F59-4121-885D-E307C1918303

Q36601787-995866FD-A852-4C44-8886-DAEE1DB78E5D

Q36601787-B6C23F04-2D55-4D19-8C0A-7E2488A4C84E

P2860

Q36601787-26D7E9B8-4070-402E-999F-21DBFD9F755F

Q36601787-288E445F-416F-45EF-8CF2-D4AA1FD682B7

Q36601787-2FF1D395-7AAB-44C8-82AE-76EEFC1732CE

Q36601787-3F1FFDBF-584A-48E1-81C4-76C369A7C5E3

Q36601787-416CD531-FFD6-4C64-8729-8CDF021041D4

Q36601787-4EBE919D-A592-447B-929A-CF45997760A5

Q36601787-51D5D6B5-D849-4B7D-A564-5B414E1B0A71

Q36601787-591541D3-F150-433E-B046-CA3C026F4F23

Q36601787-6F486F0C-29AD-4C89-9438-6EC088B226A1

Q36601787-81B0B382-C940-4122-BE83-3EBCECEDC08A

P304

Q36601787-3C81CFF2-F4A5-47F9-A253-04964FAB24C2

P31

Q36601787-F6030018-4517-4C3C-9B0A-FEDCD84E227A

P356

Q36601787-24B2EFC7-4EFA-4DD8-BD43-E53DE1ECCB9F

P407

Q36601787-97F7221F-9E4A-4F13-ADBA-0D3E036E0D83

P433

Q36601787-E303C8D8-171D-45B4-A44B-877E55E637DE

P478

Q36601787-A4140993-82BD-48F8-990A-BF2AD3AB36EF

P50

Q36601787-08991332-F569-4583-8DF0-B085D61F9423

P577

Q36601787-AFFB49CA-DC90-49BB-8C5F-C26D338C14FE

P5875

Q36601787-4F6742EC-843A-4382-8F2C-FF93D9597E8D

P698

Q36601787-01217A10-B4D1-45C0-91F5-BFF6A8FA1DC1

P932

Q36601787-9CA53E2E-CAD4-4EE1-937C-6A4AE33C7554

P356

P1433

P1476

Patterns and risk factors asso ...... among breast cancer survivors

@en

P2093

Angela DeMichele

http://www.w3.org/2001/XMLSchema#string

Brandon T Greene

http://www.w3.org/2001/XMLSchema#string

Carrie Stricker

http://www.w3.org/2001/XMLSchema#string

Deborah Bruner

http://www.w3.org/2001/XMLSchema#string

John T Farrar

http://www.w3.org/2001/XMLSchema#string

Jun J Mao

http://www.w3.org/2001/XMLSchema#string

Sharon Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation.

Management of arthralgias associated with aromatase inhibitor therapy

Immune responses and bone loss: the estrogen connection.

Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors

Aromatase inhibitor-associated arthralgia syndrome.

Modulation of pain by estrogens.

Effectively nursing patients receiving aromatase inhibitor therapy.

P304

3631-3639

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24419

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Marjorie A Bowman

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26283587

http://www.w3.org/2001/XMLSchema#string

P698

19517460

http://www.w3.org/2001/XMLSchema#string

P932

3569524

http://www.w3.org/2001/XMLSchema#string